Gubra A/S (GUBRA) - Total Liabilities
Based on the latest financial reports, Gubra A/S (GUBRA) has total liabilities worth Dkr173.94 Million DKK (≈ $27.21 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gubra A/S - Total Liabilities Trend (2019–2025)
This chart illustrates how Gubra A/S's total liabilities have evolved over time, based on quarterly financial data. See Gubra A/S current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Gubra A/S Competitors by Total Liabilities
The table below lists competitors of Gubra A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LX International Corp
KO:001120
|
Korea | ₩5.83 Trillion |
|
Sanofi India Limited
NSE:SANOFI
|
India | Rs5.06 Billion |
|
Flotek Industries Inc
NYSE:FTK
|
USA | $113.67 Million |
|
Beken Corp
SHG:603068
|
China | CN¥377.58 Million |
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
China | CN¥4.44 Billion |
|
Barclays PLC
LSE:BARC
|
UK | GBX1.62 Trillion |
|
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
|
China | CN¥3.92 Billion |
|
SeAH Bestee
KO:001430
|
Korea | ₩1.96 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Gubra A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gubra A/S stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gubra A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gubra A/S (2019–2025)
The table below shows the annual total liabilities of Gubra A/S from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr173.94 Million ≈ $27.21 Million |
+7.43% |
| 2024-12-31 | Dkr161.91 Million ≈ $25.33 Million |
+11.19% |
| 2023-12-31 | Dkr145.62 Million ≈ $22.78 Million |
-5.87% |
| 2022-12-31 | Dkr154.69 Million ≈ $24.20 Million |
+2.68% |
| 2021-12-31 | Dkr150.66 Million ≈ $23.57 Million |
+30.82% |
| 2020-12-31 | Dkr115.17 Million ≈ $18.02 Million |
+8.28% |
| 2019-12-31 | Dkr106.36 Million ≈ $16.64 Million |
-- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more